We further performed PD-L1 IHC and the results showed the patients with B2 or B3 thymomas in the cluster C4 had high PD-L1 expressions (Figure 4), which suggested patients with B2 and B3 thymomas could potentially benefit from immunotherapy (35–37). Here, CD274 is linked to thymoma.